Theravance Biopharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
TBPH$17.030.0%Stored close · as of Sep 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| | | | | | | Incorporated by Reference | ||
| ExhibitNumber | | Exhibit Description | | Filed Herewith | | Form | | FilingDate/PeriodEnd Date |
| | | | | | | | | |
| 2.1 | | Agreement and Plan of Merger, dated as of June 28, 2026, by and among Theravance Biopharma, Inc., Zymeworks Inc. and Zymeworks Merger Sub 1* | | | | 8-K | | June 29, 2026 |
| | | | | | | | | |
| 10.1+# | | Compromise Agreement, dated June 18, 2026, by and between Theravance Biopharma Ireland Limited and Áine Miller | | X | | | | |
| 10.2+# | | Special Employer Pension Contribution Letter to Áine Miller, dated June 18, 2026 | | X | | | | |
| | | | | | | | | |
| 31.1 | | Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended | | X | | | | |
| | | | | | | | | |
| 31.2 | | Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended | | X | | | | |
| | | | | | | | | |
| 32(1) | | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | | X | | | | |
| | | | | | | | | |
| 101 | | Financial statements from the quarterly report on Form 10-Q of the Company for the quarter ended June 30, 2026, formatted in iXBRL: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), (iii) Condensed Consolidated Statements of Shareholders’ Equity, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) the Notes to the Condensed Consolidated Financial Statements | | X | | | | |
| | | | | | | | | |
| 104 | | Cover Page Interactive Data File (Formatted in iXBRL and contained in Exhibit 101) | | X | | | | |
- The schedules and exhibits to the Merger Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request.
| + | Management contract or compensatory plan or arrangement. |
|---|
| # | Certain personally identifiable information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. The omitted information is indicated by “[***].” |
|---|
| (1) | The certifications provided as Exhibit 32 are being furnished to accompany the Report pursuant to 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.